Yuki Gosei Kogyo Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History 4Years Growth
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥10 | +11.1% |
| 2025 | ¥9 | +12.5% |
| 2024 | ¥8 | +14.3% |
| 2023 | ¥7 | +75.0% |
| 2022 | ¥4 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥12,839M | ¥12,932M | ¥15,128M | ¥15,448M |
| Gross Profit | ¥3,048M | ¥3,260M | ¥3,307M | ¥2,620M |
| Operating Income | ¥900M | ¥1,128M | ¥1,220M | ¥387M |
| Pretax Income | ¥691M | ¥954M | ¥1,199M | ¥504M |
| Net Income | ¥556M | ¥776M | ¥896M | ¥313M |
| EPS | ¥25.51 | ¥35.57 | ¥41.40 | ¥14.51 |
| Operating Margin | 7.01% | 8.72% | 8.06% | 2.51% |
| Balance Sheet | ||||
| Total Assets | ¥22,118M | ¥24,370M | ¥26,871M | ¥25,730M |
| Total Equity | ¥11,477M | ¥12,429M | ¥13,105M | ¥13,486M |
| Total Liabilities | ¥10,641M | ¥11,941M | ¥13,766M | ¥12,244M |
| Cash | ¥1,143M | ¥588M | ¥973M | ¥885M |
| Interest-bearing Debt | ¥5,581M | ¥6,782M | ¥8,438M | ¥6,745M |
| Equity Ratio | 51.89% | 51.00% | 48.77% | 52.41% |
| D/E Ratio | 0.49 | 0.55 | 0.64 | 0.50 |
| Cash Flow | ||||
| Operating CF | ¥668M | ¥388M | ¥2,143M | ¥2,844M |
| Investing CF | -¥1,237M | -¥1,894M | -¥3,248M | -¥1,008M |
| Financing CF | -¥158M | ¥948M | ¥1,496M | -¥1,922M |
| Free CF | -¥490M | -¥1,367M | -¥1,094M | ¥1,728M |
| Efficiency | ||||
| ROE | 4.84% | 6.24% | 6.84% | 2.32% |
| ROA | 2.51% | 3.18% | 3.33% | 1.22% |
Latest IR Information
-
Notice Regarding Disposal of Treasury Stock as Restricted Stock Awards
Announces completion of funding for treasury stock held as restricted stock awards. Disposed shares: total 25,325 shares, total amount 8,762,450 yen. Targets are 3 directors and 4 executive officers. Payment date: August 20, 2026.
Read more -
[Organic Synthesis Pharmaceuticals] FY2027 Full-Year Earnings Forecast Revision | Sales of 16,000 million yen
Organic Synthesis Pharmaceuticals Co., Ltd. revised its FY2027 full-year earnings forecast, expecting sales of 16,000 million yen and operating profit of 550 million yen. The outlook has been revised considering raw material procurement trends and geopolitical risks.
Read more -
Q1 FY2027 Financial Summary
Revenue for the first quarter of FY2027 was JPY 4,284 million, a 7.2% increase YoY. Net income was JPY 200 million, a 108.3% increase YoY. Although revenue increased, operating profit declined due to rising costs. The full-year earnings forecast is...
Read more -
[Organic Synthesis Pharmaceuticals] Share Buyback and Introduction of Compensation System | July 2026
Organic Synthesis Pharmaceuticals plans to sell 25,325 shares of common stock at 346 yen per share on August 20, 2026, and introduce a new compensation system for directors and executive officers.
Read more
Latest News (5 items)
Company Information
About
Yuki Gosei Kogyo Co., Ltd. researches, develops, manufactures, and markets amino acids, chemical products, and pharmaceuticals in Japan and internationally. It offers food additives, and industrial and agricultural chemicals; and glycine, glycine compounds, nicotinic acid amide, active pharmaceutical ingredients, nicotinamide, isoniazid, drug intermediates, and cosmetic ingredients. The company also provides pyridine, piperidine, silicon, and other compounds; DNA, nucleoside, and protamine; and active pharmaceutical ingredients. In addition, it engages in the contract manufacturing of pharmaceuticals and chemical products. Yuki Gosei Kogyo Co., Ltd. was incorporated in 1947 and is headquartered in Chuo, Japan.
